Opinion 18 Dec 2023 What to expect from biotech clinical trials in the coming year …ongoing.” Data for ocular, CNS and hearing loss disorder, AAV gene therapies could drive financing rounds, while refinements to the technology could improve manufacturing yield and reduce costs. Overall, rare… December 18, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals …of treatment in this study. Newron is an Italian-headquartered biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS)…. January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 13 Jul 2022 Paradigm of treatment of mental health to be transformed by gut-brain development program …a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain… July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2022 FDA lifts partial clinical hold on Curis lymphoma study …primary CNS lymphoma, and patients developing adaptive resistance to ibrutinib monotherapy. The goals of the study are to determine several parameters including safety, MTD, RP2D and signals of activity. Curis… August 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 TrialSpark acquires immunodermatology portfolio and creates Libertas Bio …novel therapies. TrialSpark is focused on clinical stage assets in rheumatology, dermatology, CNS, and cardiometabolic diseases, with a focus on chronic diseases that are treated outside of a hospital setting…. November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 12 Mar 2018 A Dutch Company on the Quest Against Cystic Fibrosis …use RNA in diseases affecting the central nervous system (CNS), starting with Katwijk’s disease, a rare disorder that causes strokes in middle-aged people. ProQR’s Axiomer technology “What… March 12, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2017 Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease …on’ PINK1 to the benefit of patients with Parkinson’s.” Regulatory bodies appear to be particularly tough when it comes to getting a drug targeting the CNS onto the market. But,… October 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
2024 biotech deals tracker: the latest partnerships and M&A …Shinyaku, headquartered in Japan, announced a collaboration with MiNA Therapeutics, based in the United Kingdom, to develop therapies for CNS-related rare diseases. Nippon Shinyaku is eligible for milestone payments under… March 7, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know …pipeline spans immuno-oncology and immunology with both proprietary and partnered assets; its public pipeline page highlights programs across oncology, inflammatory and fibrotic diseases, cardiometabolic, and central nervous system (CNS) indications…. September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way …validation, facilitate translation, and optimize clinical trial design in the treatment of CNS diseases. Supporting Sosei Heptares “This is an area in which we share a deep commitment and complementary… November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Cancer drug for children and young people with glioblastoma given to patients in study …which represents approximately 20% of tumors of the central nervous system (CNS) in children, continue to have a very poor prognosis with a five-year-survival rate of less than 20%. Surgery… September 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 22 Apr 2024 The biggest private biotech investments in March 2024 The companies Mirador Therapeutics, Alumis, and Sionna Therapeutics bagged the biggest private biotech investments in March 2024. Around the world, oncology and central nervous system (CNS) players attracted the biggest… April 22, 2024 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email